4/A: Twist Bioscience CEO Sells Shares to Cover Tax Obligations
SEC Form 4/A
Twist Bioscience CEO Emily M. Leproust sold 14,334 shares to cover tax obligations related to vesting Performance Stock Units.
Summary
- Twist Bioscience CEO Emily M. Leproust sold 14,334 shares of common stock at a price of $44.605 per share on November 6, 2024.
- The sale was to cover tax withholding obligations related to the vesting of Performance Stock Units (PSUs).
- These sales are mandated by the company's equity incentive plans and do not represent discretionary trades by the CEO.
- Following the transaction, Leproust directly owns 589,552 shares of Twist Bioscience common stock.
- The CEO also holds various employee stock options with different exercise prices and vesting schedules.
Sentiment
Score: 6
Explanation: The document reflects a routine transaction related to executive compensation. It is neither particularly positive nor negative for the company's outlook.
Industry Context
This is a routine transaction for executives who receive equity compensation. It is common for executives to sell shares to cover tax obligations when stock options or restricted stock units vest.
Comparison to Industry Standards
- Many biotech and tech companies use stock options and restricted stock units as part of their compensation packages.
- It is standard practice for companies to have 'sell to cover' mechanisms to handle tax obligations related to vesting equity.
- The vesting schedules and exercise prices of the options are typical for executive compensation in the industry.
- Companies like Illumina, Agilent, and Thermo Fisher Scientific also use similar equity compensation structures.
Stakeholder Impact
- The sale of shares by the CEO may have a minor impact on the stock price, but it is not expected to be significant given the reason for the sale.
- The transaction does not impact the company's operations or financial health.
Key Dates
| Date | Description |
|---|---|
| 09/01/2016 | 25% of shares subject to one of the employee stock options vested. |
| 09/28/2017 | 10% of shares subject to one of the employee stock options vested. |
| 09/28/2018 | 15% of shares subject to one of the employee stock options vested. |
| 10/31/2019 | 20% of shares subject to one of the employee stock options vested. |
| 10/24/2020 | 25% of shares subject to one of the employee stock options vested. |
| 09/01/2020 | Performance stock options granted to the reporting person. |
| 12/19/2022 | Performance stock options vested and became exercisable. |
| 11/06/2024 | Date of the stock sale transaction. |
| 11/08/2024 | Original filing date of the Form 4. |
| 11/15/2024 | Date of the amended filing. |
Keywords
Twist Bioscience, Emily M. Leproust, stock sale, tax obligations, Performance Stock Units, employee stock options, insider trading, equity incentive plans
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.